{"id":"oral-anticoagulant-direct-acting","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Dyspepsia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Direct-acting oral anticoagulants (DOACs) work by selectively inhibiting key enzymes in the coagulation cascade without requiring monitoring or cofactors like vitamin K. They provide rapid onset of anticoagulant effect and predictable pharmacokinetics, making them suitable for oral administration in conditions requiring thromboembolism prevention.","oneSentence":"Direct-acting oral anticoagulants inhibit specific clotting factors (typically Factor Xa or thrombin) to prevent blood clot formation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:46.026Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism prevention and treatment"}]},"trialDetails":[{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT05122455","phase":"PHASE2, PHASE3","title":"Effects of Edoxaban on Platelet Aggregation","status":"COMPLETED","sponsor":"University of Sao Paulo","startDate":"2021-09-14","conditions":"SCAD, AMI","enrollment":61},{"nctId":"NCT06322953","phase":"PHASE3","title":"Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage","status":"RECRUITING","sponsor":"Walton Centre NHS Foundation Trust","startDate":"2025-03-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":1084},{"nctId":"NCT05955365","phase":"PHASE4","title":"Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-12-18","conditions":"Percutaneous Coronary Intervention (PCI), Atrial Fibrillation (AF), Oral Anticoagulation","enrollment":3010},{"nctId":"NCT06220422","phase":"","title":"Assessment of a Procedure for Managing Oral Anticoagulants (NACO) in the Management of Fractures","status":"COMPLETED","sponsor":"Hôpital NOVO","startDate":"2024-02-26","conditions":"Femur Fracture","enrollment":127},{"nctId":"NCT05472766","phase":"NA","title":"Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-11-24","conditions":"Subdural Hematoma, Atrial Fibrillation","enrollment":1},{"nctId":"NCT04437303","phase":"PHASE4","title":"Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2020-11-25","conditions":"Aortic Valve Disease, Aortic Valve Stenosis, Stroke","enrollment":858},{"nctId":"NCT06383741","phase":"","title":"Predicting Outcomes in ICH Patients on Direct Factor Xa Inhibitors","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-07-10","conditions":"Intra Cerebral Hemorrhage","enrollment":200},{"nctId":"NCT00839163","phase":"PHASE2","title":"Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Venous Thrombosis, Deep Vein Thrombosis","enrollment":613},{"nctId":"NCT05112666","phase":"","title":"A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-12-02","conditions":"Treatment of Venous Thromboembolism in Cancer Patients","enrollment":2601},{"nctId":"NCT01442792","phase":"PHASE2","title":"Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10-12","conditions":"Cardiovascular Disease, Coronary Artery Disease","enrollment":108},{"nctId":"NCT05189002","phase":"PHASE2","title":"A Study to Evaluate Dimolegin in Prevention of Thromboembolic Complications During Knee Replacement","status":"UNKNOWN","sponsor":"PharmaDiall Ltd.","startDate":"2019-05-31","conditions":"Venous Thromboembolism","enrollment":240},{"nctId":"NCT05307718","phase":"","title":"Pharmacogenomics in Prediction of Cardiovascular Drugs Adverse Reaction","status":"UNKNOWN","sponsor":"Clinical Hospital Centre Zagreb","startDate":"2020-12-15","conditions":"Pharmacogenetics, Drug-Related Side Effects and Adverse Reactions, Cardiovascular Drugs","enrollment":1200},{"nctId":"NCT05088928","phase":"PHASE2","title":"Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care","status":"UNKNOWN","sponsor":"Scotmann Pharmaceuticals","startDate":"2022-03-01","conditions":"COVID-19","enrollment":40},{"nctId":"NCT04191928","phase":"PHASE1","title":"Pharmacokinetics of Apixaban in Patients Undergoing Pancreaticoduodenectomy","status":"COMPLETED","sponsor":"Thomas Jefferson University","startDate":"2020-03-03","conditions":"Pancreas Cancer, DVT, Pulmonary Embolism","enrollment":4},{"nctId":"NCT03926156","phase":"PHASE3","title":"RIvoraxaban in Mitral Stenosis","status":"TERMINATED","sponsor":"Rajaie Cardiovascular Medical and Research Center","startDate":"2019-05-22","conditions":"Mitral Stenosis, Rheumatic Heart Disease, Atrial Fibrillation","enrollment":40},{"nctId":"NCT03284762","phase":"","title":"Xarelto on Prevention of Stroke and Noncentral Nervous System Systemic Embolism in Treatment-naïve Asian Patients With Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-09-11","conditions":"Atrial Fibrillation","enrollment":1216},{"nctId":"NCT03119116","phase":"","title":"Use of Direct Oral Anticoagulants in UK","status":"COMPLETED","sponsor":"Bayer","startDate":"2017-05-15","conditions":"Stroke","enrollment":31336},{"nctId":"NCT02635230","phase":"","title":"What is the Optimal antiplatElet and Anticoagulant Therapy in Patients With Oral Anticoagulation Undergoing revasculariSaTion 2.","status":"UNKNOWN","sponsor":"R&D Cardiologie","startDate":"2014-06","conditions":"Atrial Fibrillations, Heart Valve Prostheses, Acute Coronary Syndromes","enrollment":2200},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT02157272","phase":"PHASE3","title":"Rivaroxaban in Thrombotic Antiphospholipid Syndrome","status":"TERMINATED","sponsor":"University of Padova","startDate":"2014-12","conditions":"Antiphospholipid Syndrome","enrollment":121},{"nctId":"NCT02128841","phase":"PHASE2","title":"Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.","status":"TERMINATED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2012-09","conditions":"Aortic Valve Disease, Heart Valve Prosthesis Implantation, Anticoagulants","enrollment":12},{"nctId":"NCT00641732","phase":"PHASE2","title":"Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement","status":"COMPLETED","sponsor":"Takeda","startDate":"2007-10","conditions":"Venous Thromboembolism","enrollment":1045},{"nctId":"NCT00786422","phase":"PHASE2","title":"Deep Vein Thrombosis Treatment With the Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients Using a Strong CYP 3A4 Inducer","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-05","conditions":"Venous Thrombosis, Deep Vein Thrombosis","enrollment":25},{"nctId":"NCT02379663","phase":"PHASE4","title":"Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-01","conditions":"Osteoarthritis, Hip, Femur Head Necrosis, Femoral Neck Fractures","enrollment":639},{"nctId":"NCT01954238","phase":"PHASE1","title":"A Study to Access Safety, Tolerability, Pharmacokinetics(PK) and Pharmacodynamics(PD) of Orally Administered GCC-4401C in Healthy Volunteers","status":"COMPLETED","sponsor":"Green Cross Corporation","startDate":"2013-08","conditions":"Healthy Volunteers","enrollment":46},{"nctId":"NCT00402467","phase":"PHASE2","title":"An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-02","conditions":"Venous Thromboembolism","enrollment":613},{"nctId":"NCT00839826","phase":"PHASE2","title":"ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Thromboembolism, Prevention","enrollment":641},{"nctId":"NCT00439725","phase":"PHASE3","title":"Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-02","conditions":"Venous Thromboembolism","enrollment":1197},{"nctId":"NCT00395772","phase":"PHASE2","title":"Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-12","conditions":"Venous Thromboembolism","enrollment":543},{"nctId":"NCT02221102","phase":"PHASE2, PHASE3","title":"Edoxaban for TIA and Acute Minor Stroke","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2013-12","conditions":"Ischemia, Stroke, Cerebral Infarction","enrollment":3700},{"nctId":"NCT00440193","phase":"PHASE3","title":"Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-03","conditions":"Venous Thrombosis","enrollment":3449},{"nctId":"NCT00439777","phase":"PHASE3","title":"Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Pulmonary Embolism - The EINSTEIN PE Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2007-03","conditions":"Pulmonary Embolism","enrollment":4833},{"nctId":"NCT01924325","phase":"PHASE2, PHASE3","title":"Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in Acute Non-disabling Cerebrovascular Events","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2014-01","conditions":"Ischemic Stroke, TIA","enrollment":10000},{"nctId":"NCT01923818","phase":"PHASE2, PHASE3","title":"Treatment of Rivaroxaban Versus Aspirin for Non-disabling Cerebrovascular Events","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2013-09","conditions":"Ischemic Stroke, TIA","enrollment":3700},{"nctId":"NCT00541320","phase":"PHASE2","title":"Phase IIa Venous Thromboembolism (VTE) Prevention Study In Total Knee Replacement (TKR)","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2007-02","conditions":"Venous Thromboembolism","enrollment":""},{"nctId":"NCT00353678","phase":"PHASE2","title":"Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2006-06","conditions":"Thromboembolism","enrollment":1141},{"nctId":"NCT00448214","phase":"PHASE2","title":"Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2007-03","conditions":"Atrial Fibrillation","enrollment":448},{"nctId":"NCT00942435","phase":"PHASE3","title":"A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-06","conditions":"Venous Thromboembolism","enrollment":156},{"nctId":"NCT01028950","phase":"PHASE3","title":"YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2009-05","conditions":"Venous Thromboembolism","enrollment":52},{"nctId":"NCT00252005","phase":"PHASE2","title":"Oral Direct Factor Xa-inhibitor Apixaban in Patients With Acute Symptomatic Deep-vein Thrombosis-The Botticelli DVT Study","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-11","conditions":"Deep-Vein Thrombosis","enrollment":520}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["HMG-CoA reductase inhibitors","platelet aggregation inhibitors from the P2Y12 receptor antagonist group"],"phase":"phase_3","status":"active","brandName":"Oral Anticoagulant, Direct-Acting","genericName":"Oral Anticoagulant, Direct-Acting","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Direct-acting oral anticoagulants inhibit specific clotting factors (typically Factor Xa or thrombin) to prevent blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism prevention and treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}